Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer

Yahagi,Masashi; Tsuruta,Masashi; Hasegawa,Hirotoshi; Okabayashi,Koji; Kitagawa,Yuko

doi:10.3892/mco.2017.1177

Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer

Authors:
- Masashi Yahagi
- Masashi Tsuruta
- Hirotoshi Hasegawa
- Koji Okabayashi
- Yuko Kitagawa
View Affiliations

Affiliations: Department of Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan
Published online on: March 1, 2017 https://doi.org/10.3892/mco.2017.1177
Pages: 529-533

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver dysfunction that may affect drug metabolism is a major concern in patients treated with chemotherapy. Thus, assessment of the degree of liver dysfunction is crucial for predicting the adverse events of chemotherapy. The non‑alcoholic fatty liver disease fibrosis score (NFS) is a non‑invasive clinical scoring system constructed from routine clinical and laboratory variables. The aim of this study was to evaluate whether NFS was useful for predicting the adverse events of chemotherapy including irinotecan (CPT‑11) for colorectal cancer. Between January, 2007 and May, 2013, a total of 87 patients with unresectable/recurrent colorectal cancer who received first‑line chemotherapy including CPT‑11 were reviewed. Demographic variables, including pretreatment NFS, were retrospectively collected from medical records. The primary outcome was the association between pretreatment NFS and adverse events, such as hematological and non‑hematological toxicity, of chemotherapy including CPT‑11. The median pretreatment NFS was 1.302 (range, 5.158-2.620). Pretreatment NFS was an independent risk factor for hematological toxicity in a multivariate analysis (coefficient=0.932, 95% CI: 0.083‑1.781; P=0.031). Receiver operating characteristic curve analysis identified 0.347 as the optimal cut‑off value associated with hematological toxicity. Using this cut‑off, high NFS was found to be a significant risk factor for hematological toxicity (coefficient=2.019, 95% CI: 0.239‑3.798, P=0.026), but not for non‑hematological toxicity (P=0.546). Therefore, based on these results, NFS appears to be a significant predictor of hematological adverse events in chemotherapy including CPT‑11 for colorectal cancer and it is a non‑invasive, useful tool that may be used for determining regimens or doses of chemotherapy including CPT-11.

View Figures

View References

1	Al Knawy B and Shiffman M: Percutaneous liver biopsy in clinical practice. Liver Int. 27:1166–1173. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F and Poynard T; LIDO Study Group, : Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 128:1898–1906. 2005. View Article : Google Scholar : PubMed/NCBI
3	McPherson S, Stewart SF, Henderson E, Burt AD and Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 59:1265–1269. 2010. View Article : Google Scholar : PubMed/NCBI
4	Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP and George J: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 145:782–789.e4. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, et al: Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 48:1051–1060. 2013. View Article : Google Scholar : PubMed/NCBI
6	Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A16 and 28. Pharmacogenet Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
7	Cancer Therapy Evaluation Program (CTEP), . N.C.I. Adverse Events (CTCAE) Version 4.0. 2009 June 14, 2010 [cited 2009 May 28]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
8	Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ and Kastrissios H: Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 72:638–647. 2002. View Article : Google Scholar : PubMed/NCBI
9	Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar : PubMed/NCBI
10	Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T and Maeda Y: Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett. 3:694–698. 2012.PubMed/NCBI
11	Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
12	Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, et al: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 14:136–142. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ and Gobburu JV: The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 47:78–86. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, et al: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 75:501–515. 2004. View Article : Google Scholar : PubMed/NCBI
15	Bosma PJ, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J and Komamura K: Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 269:17960–17964. 1994.PubMed/NCBI
16	Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP and Fuchs CS: Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 22:1439–1446. 2004. View Article : Google Scholar : PubMed/NCBI
17	Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M and Armand JP: Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol. 20:4303–4312. 2002. View Article : Google Scholar : PubMed/NCBI
18	Hao H, Zhang L, Jiang S, Sun S, Gong P, Xie Y, Zhou X and Wang G: Thioacetamide intoxication triggers transcriptional up-regulation but enzyme inactivation of UDP-glucuronosyltransferases. Drug Metab Dispos. 39:1815–1822. 2011. View Article : Google Scholar : PubMed/NCBI
19	Xie Y, Wang G, Wang H, Yao X, Jiang S, Kang A, Zhou F, Xie T and Hao H: Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the counteracting effects of hepatoprotective agents. Drug Metab Dispos. 40:796–802. 2012. View Article : Google Scholar : PubMed/NCBI
20	Ikuno N, Soda H, Watanabe M and Oka M: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst. 87:1876–1883. 1995. View Article : Google Scholar : PubMed/NCBI
21	Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56:3752–3757. 1996.PubMed/NCBI
22	Li M, Wang Z, Guo J, Liu J, Li C, Liu L, Shi H, Liu L, Li H, Xie C, et al: Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther. 7:1653–1661. 2014.PubMed/NCBI
23	Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S and Ghiringhelli F: Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol. 20:1565–1573. 2014. View Article : Google Scholar : PubMed/NCBI
24	Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, Sato Y, Najima M, Ura T and Muro K: Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 45:1757–1763. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Wang WS: UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 112:1932–1940. 2008. View Article : Google Scholar : PubMed/NCBI